New lung cancer indication for Tarceva

The licence for Tarceva (erlotinib) has been extended to include maintenance therapy in non-small cell lung cancer (NSCLC). It can now be used as monotherapy in patients with locally advanced or metastatic NSCLC with stable disease after four cycles of standard platinum-based first-line chemotherapy.

Tarceva is also licensed for the treatment of locally advanced or metastatic NSCLC after failure of at least one chemotherapy regimen, and in combination with gemcitabine for metastatic pancreatic cancer.

View Tarceva drug record

Further information: Roche